Epidemiology of Extended-Spectrum β-Lactamase Producing Escherichia coli in the Stools of Returning Japanese Travelers, and the Risk Factors for Colonization
Objective Travel overseas has recently been considered a risk factor for colonization with drug-resistant bacteria. The purpose of this study was to establish the epidemiology and risk factors associated with the acquisition of drug-resistant bacteria by Japanese travelers. Methods Between October 2011 and September 2012, we screened the stools of 68 Japanese returning travelers for extended-spectrum β-lactamase (ESBL) producing Escherichia coli. All specimens were sampled for clinical reasons. Based on the results, the participants were divided into an ESBL-producing E. coli positive group (18 cases; 26%) and an ESBL-producing E. coli negative group (50 cases; 74%), and a case-control study was performed. Microbiological analyses of ESBL-producing strains, including susceptibility tests, screening tests for metallo-β-lactamase, polymerase chain reaction amplification and sequencing of blaCTX-M genes, multilocus sequence typing, and whole genome sequencing, were also conducted. Results In a univariate comparison, travel to India was a risk factor (Odds Ratio 13.6, 95% Confidence Interval 3.0–75.0, p<0.0001). There were no statistical differences in the characteristics of the travel, such as backpacking, purpose of travel, interval between travel return and sampling stool, and duration of travel. Although 10 of 13 analyzed strains (77%) produced CTX-M-15, no ST131 clone was detected. Conclusion We must be aware of the possibilities of acquiring ESBL-producing E. coli during travel in order to prevent the spread of these bacteria not only in Japan but globally.
References
[1]
Laupland KB, Church DL, Vidakovich J, Mucenski M, Pitout JD (2008) Community-onset extended-spectrum β-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 57: 441–448. doi: 10.1016/j.jinf.2008.09.034
[2]
Tham J, Walder M, Melander E, Odenholt I (2012) Duration of colonization with extended-spectrum β-lactamase-producing Escherichia coli in patients with travellers’ diarrhoea. Scand J Infect Dis 44: 573–577. doi: 10.3109/00365548.2011.653582
[3]
Walsh TR, Weeks J, Livermore DM, Toleman MA (2011) Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 11: 355–362. doi: 10.1016/s1473-3099(11)70059-7
[4]
Hawkey PM (2008) Prevalence and clonality of extended-spectrum β-lactamases in Asia. Clin Microbiol Infect 14 Suppl 1159–165. doi: 10.1111/j.1469-0691.2007.01855.x
[5]
Woodford N (2011) Unwanted souvenirs travel and multi-resistant bacteria. J Travel Med 18: 297–298. doi: 10.1111/j.1708-8305.2011.00541.x
[6]
Donnenberg MS (2009) Enterobactriacae. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone. 2815–2833.
[7]
Clinical and Laboratory Standards Institute (2011) Methods For Dilution Antimicrobial Susceptibility Tests For Bacteria That Grow Aerobically. CLSI document M7-A9. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania.
[8]
Clinical and Laboratory Standards Institute (2010) Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania.
[9]
Kimura S, Ishii Y, Yamaguchi K (2005) Evaluation of dipicolinic acid for detection of IMP- or VIM- type metallo-β-lactamase-producing Pseudomonas aeruginosa clinical isolates. Diagn Microbiol Infect Dis. 53: 241–244. doi: 10.1016/j.diagmicrobio.2005.05.017
[10]
Xu L, Ensor V, Gossain S, Nye K, Hawkey P (2005) Rapid and simple detection of blaCTX-M genes by multiplex PCR assay. J Med Microbiol. 54: 1183–1187.
[11]
Saladin M, Cao VT, Lambert T, Donay JL, Herrmann JL, et al. (2002) Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol Lett 209: 161–168. doi: 10.1111/j.1574-6968.2002.tb11126.x
[12]
Tritt A, Eisen JA, Facciotti MT, Darling AE (2012) An integrated pipeline for de novo assembly of microbial genomes. PLoS One. 7: e42304. doi: 10.1371/journal.pone.0042304
[13]
Kanda Y (2012) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 1–7.
[14]
T？ngdén T, Cars O, Melhus A, L？wdin E (2010) Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum β-lactamases a prospective study with Swedish volunteers. Antimicrob Agents Chemother 54: 3564–3568. doi: 10.1128/aac.00220-10
[15]
Peirano G, Laupland KB, Gregson DB, Pitout JD (2011) Colonization of Returning Travelers With CTX-M-Producing Escherichia coli. J Travel Med 18: 299–303. doi: 10.1111/j.1708-8305.2011.00548.x
[16]
Weisenberg SA, Mediavilla JR, Chen L, Alexander EL, Rhee KY, et al. (2012) Extended spectrum β-lactamase-producing enterobacteriaceae in international travelers and non-travelers in New York City. PLoS One 7: e45141. doi: 10.1371/journal.pone.0045141
[17]
Ostholm-Balkhed A, T？rnberg M, Nilsson M, Nilsson LE, Hanberger H, et al. (2013) Travel-associated faecal colonization with ESBL-producing Enterobacteriaceae incidence and risk factors. J Antimicrob Chemother 68: 2144–2153. doi: 10.1093/jac/dkt167
[18]
Luvsansharav UO, Hirai I, Niki M, Nakata A, Yoshinaga A, et al. (2011) Prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among healthy adult people in Japan. J Infect Chemother 17: 722–725. doi: 10.1007/s10156-011-0225-2
[19]
Islam S (2012) High rates of ESBL-producing Escherichia coli in young children who traveled recently to India. Pediatr Infect Dis J 31: 1103. doi: 10.1097/inf.0b013e3182610e20
[20]
Freeman JT, McBride SJ, Heffernan H, Bathgate T, Pope C, et al. (2008) Community-onset genitourinary tract infection due to CTX-M-15-producing Escherichia coli among travelers to the Indian subcontinent in New Zealand. Clin Infect Dis 47: 689–692. doi: 10.1086/590941
[21]
Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, et al. (2009) Emergence of high levels of extended-spectrum-β-lactamase-producing Gram-negative bacilli in the Asia-Pacific region data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 53: 3280–3284. doi: 10.1128/aac.00426-09
[22]
Brink AJ, Botha RF, Poswa X, Senekal M, Badal RE, et al. (2012) Antimicrobial susceptibility of Gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004–2009) impact of the new carbapenem breakpoints. Surg Infect (Larchmt) 13: 43–49. doi: 10.1089/sur.2011.074
[23]
Deresinski S (2011) Travels with ESBLs. Clin Infect Dis 52: iii–iv.
[24]
Ensor VM, Shahid M, Evans JT, Hawkey PM (2006) Occurrence, prevalence and genetic environment of CTX-M β-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 58: 1260–1263. doi: 10.1093/jac/dkl422
[25]
Chong Y, Yakushiji H, Ito Y, Kamimura T (2011) Clinical and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a long-term study from Japan. Eur J Clin Microbiol Infect Dis 30: 83–87. doi: 10.1007/s10096-010-1057-1
[26]
Shibata N, Kurokawa H, Doi Y, Yagi T, Yamane K, et al. (2006) PCR classification of CTX-M-type β-lactamase genes identified in clinically isolated Gram-negative bacilli in Japan. Antimicrob Agents Chemother 50: 791–795. doi: 10.1128/aac.50.2.791-795.2006
[27]
Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, et al. (2009) Change in the prevalence of extended-spectrum-β-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother 63: 72–79. doi: 10.1093/jac/dkn463
[28]
Coque TM, Novais A, Carattoli A, Poirel L, Pitout J, et al. (2008) Dissemination of clonally related Escherichia coli strains expressing extended-spectrum β-lactamase CTX-M-15. Emerg Infect Dis 14: 195–200. doi: 10.3201/eid1402.070350
[29]
Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, et al. (2008) Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 61: 273–281. doi: 10.1093/jac/dkm464
[30]
Pitout JD, Campbell L, Church DL, Gregson DB, Laupland KB (2009) Molecular characteristics of travel-related extended-spectrum-β-lactamase-producing Escherichia coli isolates from the Calgary Health Region. Antimicrob Agents Chemother 53: 2539–2543. doi: 10.1128/aac.00061-09
